The global meningococcal vaccines market is anticipated to witness growth over the forecast period. Manufacturing quality vaccines at affordable prices, various public private partnerships for carrying out research and development activities and presence of vaccines in pipeline and their expected commercialization such as MenACWY are the key factors driving the growth of the market. Furthermore, presence of various government awareness programs, increasing government interventions in refining healthcare infrastructure and incorporation of security guidelines pertaining to meningococcal vaccines are expected to positively reinforce market growth. Growing incidences and mortality rates due to meningococcal diseases have caused the federal government to involve and support R&D initiatives and distribution of meningococcal vaccines. For instance, introduction of MenA Conjugate Vaccine Programs in Africa is expected to prevent 123,000 deaths by 2018.
Vaccines are formulated as bivalent (group A and C) or quadrivalent (groups A, C, Y, W-135) thus, global meningococcal market is segmented on the basis of types of vaccines such as bivalent, quadrivalent (polysaccharides and conjugate), Serogroup A, Serogroup B, and Serotype X. Quadrivalent market is expected to witness lucrative growth over the forecast period owing to the presence of high unmet needs and lack of availability of alternate vaccines. Various brands such as Mentactra, Menveo, Trumenba and Mentlibrix and Menoveo are available in the market for the treatment of meningococcal. Menactra is licensed for administration in age group from 9 months to 55 years old. MPSV4 is the only vaccine approved for use in people above 55 years as well as for 2 to 55 yrs. Novartis developed Baxsero which is an approved conjugate vaccine has proved beneficial in treatment of meningitis and is the first Serogroup B vaccine to be included in the national immunization program.
Meningococcal disease is caused by bacteria Neisseria meningitides and occurs sporadically throughout the world. North America is expected to lead the global meningococcal vaccines market due to increasing government interventions and prevention programs, research and development initiatives by various manufacturers. Group B vaccines have been custom made against specific epidemic strains and are used to control specific out brakes in Cuba, New Zealand, Chile, France, Brazil and Norway. In Industrialized countries, specifically Australia, Canada and European countries, incidences of meningococcal diseases were falling prior to the introduction of the vaccine, which further accelerated the fall of occurrence of the disease. This is followed by rest of the world comprising of Latin America, Middle East and African countries. Asia-Pacific is expected to be the fastest growing market due to drivers such as low manufacturing cost and increasing healthcare spending.
Some key market players functional in the meningococcal vaccines market are Neuron Biotech, Baxter international, Pfizer Inc., Novartis International, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., and Serum Institute of India Ltd. Pfizer Inc. is currently working on developing a vaccine named MnBrLP2086 which is under phase III clinical trial and is granted the breakthrough therapy status by FDA.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.